Newswise — A new study by Burke Neurological Institute (BNI), Weill Cornell Medicine, finds that activation of MAP2K signaling by genetic engineering or non-invasive repetitive transcranial magnetic stimulation (rTMS) promotes corticospinal tract (CST) axon sprouting and functional regeneration after spinal cord injury (SCI) in mice. rTMS is a noninvasive technique that evokes an electrical field in brain tissue via electromagnetic induction. While an increasing body of evidence suggests that rTMS applied over motor cortex may be beneficial for functional recovery in SCI patients, the molecular and cellular mechanisms that underlie rTMS’ beneficial effects remains unclear. This study published in Science Translation Medicine showed that high-frequency rTMS (HF-rTMS) activated MAP2K signaling and enhanced axonal regeneration and functional recovery, suggesting that rTMS might be a valuable treatment option for SCI individuals.
Facilitating axon regeneration in the injured central nervous system (CNS) remains a challenging task. The failure of mature CNS neurons to activate cell-intrinsic growth mechanisms and regenerate injured axons severely hinders functional recovery after a traumatic brain or spinal cord injury, which requires the development of effective new therapies.
The RAF – Mitogen-activated protein kinase kinase (MAP2K, also known as MEK) signaling cascade mediates long distance axon outgrowth in developing PNS and CNS neurons. Based on their previous findings, researchers from BNI hypothesized that RAF signaling regulates an intrinsic axon growth program and that its activation could enable re-growth of adult mammalian CNS axons after SCI. They found that conditional expression of a constitutively kinase-activated BRAF in mature corticospinal neurons (CSNs) elicited the expression of a set of transcription factors previously implicated in the regeneration of zebrafish retinal ganglion cell axons. In addition, conditional BRAF activation in CSNs enabled CST axon sprouting and regeneration in different experimental models of SCI in mice. According to Xiaofei Guan, MD, PhD, a postdoctoral research fellow at BNI who conducted the experiments, newly sprouting CST axons formed synapses with local spinal circuits and further resulted in improved motor functional recovery.
rTMS has been emerging as a promising strategy to enhance recovery in patients with spinal cord or brain injury, but the underlying plasticity mechanisms and the full therapeutic potential of these approaches remain unknown. The BNI research team found that a course of daily high-frequency rTMS sessions activated MAP2K signaling and modulated the expression of a set of regeneration-related transcription factors in the same way as genetic BRAF activation. Endogenous MAP2K activity was required for enhanced CST sprouting, regeneration and functional recovery in HF-rTMS treated SCI model mice.
The researchers believe these results collectively demonstrate a central role of MAP2K signaling in augmenting the growth capacity of mature CSNs, and suggest that HF-rTMS might have potential for treating spinal cord injury by modulating MAP2K signaling. The BNI team has begun clinical trials testing the HF-rTMS protocol on able-bodied individuals and SCI patients. If successful, HF-rTMS could emerge as a non-invasive, low risk treatment option to facilitate axon regeneration, alone or in combination with other additional interventions, for SCI or other individuals who may benefit from CNS circuitry repair.
This study was supported by grants from the National Institutes of Health, the New York State Department of Health Spinal Cord Injury Research Board, the Craig H. Neilsen Foundation, the Wings for Life Research Foundation, the Goldsmith Research Foundation and the Burke Foundation.
About Burke Neurological Institute
The Burke Neurological Institute is based in White Plains, NY, and was established in 1978 by Dr. Fletcher McDowell as a research institute dedicated to finding cures for chronic neurological disabilities. The Institute transforms groundbreaking research into clinical treatments so that people can see, talk, and walk again. Their goal is to combine the most rigorous, contemporary brain science with heartfelt compassionate care to innovate and develop novel cures for stable disability in those afflicted with neurological conditions such as stroke, traumatic brain injury or spinal cord injury. Burke Neurological Institute is an academic affiliate of Weill Cornell Medicine.
RSS